InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a research report issued on Monday. The brokerage set a “sell” rating on the stock.

Separately, Piper Sandler restated an “overweight” rating and issued a $4.50 price objective on shares of InspireMD in a research report on Tuesday, September 17th.

InspireMD Price Performance

NSPR opened at $2.75 on Monday. The firm has a market capitalization of $68.56 million, a P/E ratio of -3.62 and a beta of 0.90. InspireMD has a one year low of $1.81 and a one year high of $3.85. The company has a fifty day moving average price of $2.79 and a 200-day moving average price of $2.51.

InspireMD (NYSE:NSPR) last posted its earnings results on Tuesday, August 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The business had revenue of $1.74 million for the quarter, compared to analysts’ expectations of $1.74 million. InspireMD had a negative return on equity of 62.02% and a negative net margin of 388.67%. During the same quarter in the previous year, the firm earned ($0.24) earnings per share. On average, analysts expect that InspireMD will post -0.82 earnings per share for the current year.

Institutional Investors Weigh In On InspireMD

An institutional investor recently bought a new position in InspireMD stock. Mesirow Financial Investment Management Inc. acquired a new stake in InspireMD, Inc. (NYSE:NSPR) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 30,000 shares of the company’s stock, valued at approximately $71,000. Mesirow Financial Investment Management Inc. owned approximately 0.13% of InspireMD as of its most recent filing with the SEC. Institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.